Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era
| Autor: | Elizabeth A. Platz, Meir J. Stampfer, Michael F. Leitzmann, Walter C. Willett, Michael Pollak, Edward Giovannucci |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Male
Oncology Cancer Research medicine.medical_specialty medicine.medical_treatment Enzyme-Linked Immunosorbent Assay Sensitivity and Specificity Insulin-like growth factor Prostate cancer Predictive Value of Tests Risk Factors Internal medicine Biomarkers Tumor medicine Humans Prospective Studies Insulin-Like Growth Factor I Prospective cohort study Aged Aged 80 and over Hematology business.industry Binding protein Growth factor Prostatic Neoplasms Middle Aged Prostate-Specific Antigen medicine.disease Insulin-Like Growth Factor Binding Protein 3 Case-Control Studies Binding protein 3 Plasma insulin business |
| Zdroj: | Cancer Causes & Control. 16:255-262 |
| ISSN: | 1573-7225 0957-5243 |
| Popis: | The insulin-like growth factor (IGF) axis is thought to contribute to the growth and progression of prostate cancer. Some prospective studies support a direct association between IGF-1 and prostate cancer, in particular advanced disease, whereas both inverse and direct associations with prostate cancer have been reported for insulin-like growth factor binding protein-3 (IGFBP-3), the major IGF-1 binding protein in circulation. We prospectively investigated the associations of plasma IGF-1 and IGFBP-3 concentrations with prostate cancer detected in the PSA era.We identified 462 prostate cancer cases diagnosed after providing a blood specimen in 1993, but before January 1998 among men in the Health Professionals Follow-up Study. Controls were 462 age-matched men without prostate cancer who had had a PSA test after providing a blood specimen. We measured plasma concentrations of IGF-1 and IGFBP-3 by ELISA. Conditional logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI) of prostate cancer.Men with higher concentrations of IGF-1 (comparing extreme quartiles OR=1.37, 95% CI 0.92-2.03, p-trend=0.05) and IGFBP-3 (OR=1.62, 95% CI 1.07-2.46, p-trend=0.08) had a higher risk of prostate cancer. After mutual statistical adjustment, these associations were attenuated for both IGF-1 (OR=1.17, 95% CI 0.69-1.99, p-trend=0.29) and IGFBP-3 (OR=1.40, 95% CI 0.80-2.44, p-trend=0.56). We found no significant association of IGF-1 with regionally invasive or metastatic (/=T3b, N1, or M1) prostate cancer, although the number of these cases was small (n=42).Our findings for IGF-1 and prostate cancer diagnosed in the PSA era are similar to most previous studies, albeit weaker in magnitude. Our suggestive positive findings for IGFBP-3 are similar to some studies, but in direct contrast to others. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink